Trials / Completed
CompletedNCT00432627
Impact of Hepatic Impairment on the Pharmacokinetics of Deferasirox.
An Open-label, Single-dose, Parallel-group Study to Assess the Pharmacokinetics of 20 mg/kg Oral Deferasirox in Patients With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic Function
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 24 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Accepted
Summary
This study is to assess the pharmacokinetics of deferasirox in hepatically impaired patients compared to healthy volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Deferasirox | one dose of 20 mg/kg/day |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2007-02-08
- Last updated
- 2020-12-09
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00432627. Inclusion in this directory is not an endorsement.